The DOI matches its Crossref record; 10 of the 15 references it cites were found in a registry or an index.
Clinical Practice Guidelines for the management of Depression
Open accessAbstract
Participants of expert group on CPG for Depression Gautam Saha, I.D Gupta, Navendu Gaur, Tushar Jagawat, Anita Gautam, T. S Sathyanarayana Rao INTRODUCTION Depression is a common disorder, which often leads to poor quality of life and impaired role functioning. It is known to be a major contributor to the global burden of diseases and according to World Health Organization (WHO), depression is the fourth leading cause of disability worldwide and it is projected that by 2020, it will be the second most common leading cause of disability. Depression is also associated with high rates of suicidal behaviour and mortality. When depression occurs in the context of medical morbidity, it is associated with increased health care cost, longer duration of hospitalization, poor cooperation in treatment, poor treatment compliance and high rates of morbidity. Depression is also known to be associated with difficulties in role transitions (e.g., low education, high teen child-bearing, marital disruption, unstable employment) and poor role functioning (e.g., low marital quality, low work performance, low earnings). It is also reported to be a risk factor for the onset and persistence of a wide range of secondary disorders. Available data also suggests that between one-third and one-half of patients also experience recurrence of depressive episodes. ASSESSMENT AND EVALUATION (table-1)Table 1: Components of assessment and evaluationManagement of depression involves comprehensive assessment and proper establishment of diagnosis. The assessment must be based on detailed history, physical examination and mental state examinations. History must be obtained from all sources, especially the family. The diagnosis must be recorded as per the current diagnostic criteria. Depression often presents with a combination of symptoms of depressed mood, loss of interest or pleasure, decreased energy and fatigue, reduced concentration and attention, reduced self-esteem and self-confidence, ideas of guilt and unworthiness, bleak and pessimistic views of the future, ideas or acts of self-harm or suicide, disturbed sleep and diminished appetite. Depending on the severity of depression some of these symptoms may be more marked and develop characteristic features that are widely regarded as having special clinical significance. These symptoms are known as somatic symptoms of depression and include symptoms of loss of interest or pleasure in activities that are normally enjoyable, lack of emotional reactivity to normally pleasurable surroundings and events, waking up in the morning 2 hours or more before the usual time, depression worse in the morning, objective evidence of definite psychomotor retardation or agitation (remarked on or reported by other people), marked loss of appetite, weight loss (often defined as 5% or more of body weight in the past month) and marked loss of libido. It is important to note that for the diagnosis of depressive disorder these symptoms need to be present for at least 2 weeks and need to be associated with psychosocial dysfunction. Some of the patients with depression may present with predominant complaints of aches, pains and fatigue and they may not report sadness of mood on their own. A careful evaluation of these patients often reveals the underlying features of depression. However, it is important to note that many patients with depression will also have associated anxiety symptoms. With increasing severity of depression patients may report psychotic symptoms and may also present with catatonic features. Thorough assessment also ought to focus on evaluation for comorbid substance abuse/dependence. Careful history of substance intake need to be taken to evaluate the relationship of depression with substance intoxication, withdrawal and abstinence. Whenever required appropriate tests like, urine or blood screens (with prior consent) may be used to confirm the existence of comorbid substance abuse/dependence. Many physical illnesses are known to have high rates of depression. In some situations the physical illnesses have causative role in development of depression, whereas in other situations the relationship/co-occurrence is due to common etiology. Some of the physical illnesses commonly associated with depression are listed in Table-2. When depression occurs in relation to physical illness attempt may be made to clearly delineate the symptoms of depression and physical illness. Further, while making the diagnosis, it maybe clearly mentioned as to which diagnostic approach [i.e., inclusive approach (symptoms are counted whether or not they might be attributable to physical illness), substitute approach (nonsomatic symptoms are substituted with somatic symptoms), exclusive approach (somatic symptoms are deleted from the diagnostic criteria) or best estimate approach] was followed. Further, while reviewing the treatment history of medical illnesses, medication induced depression must be kept in mind, as many medic
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Treatment-resistant depression, mania, and schizophrenia, including clozapine-resistant schizophrenia, are well-recognized indications,[1-6] with evidence from comparative trials (comparison across types of ECT or with waitlisted patients).”
From Clinical Practice Guidelines for the Use of Electroconvulsive Therapy (2023) · cites this paper as [1]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Epidemiology of Depression Across Cultures
Kessler, R. C., & Bromet, E. J. (2013) · Annual Review of Public Health · doi:10.1146/annurev-publhealth-031912-114409 · Cited by 2,657
Kennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., Hasnain, M., Jollant, F., Levitt, A. J., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659417 · Cited by 1,181
Kennedy, S. H., Lam, R. W. M., Parikh, S. V., Patten, S. B., & Ravindran, A. V. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.043 · Cited by 529
Lam, R. W., Kennedy, S. H., Grigoriadis, S., McIntyre, R. S., Milev, R., Ramasubbu, R., Parikh, S. V., Patten, S. B., & Ravindran, A. V. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.041 · Cited by 431
Australian and New Zealand Clinical Practice Guidelines for the Treatment of Depression
Ellis, P., & Australian, R. (2004) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/j.1440-1614.2004.01377.x · Cited by 231
Parikh, S. V., Segal, Z. V., Grigoriadis, S., Ravindran, A. V., Kennedy, S. H., Lam, R. W., & Patten, S. B. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.042 · Cited by 183
An overview of Indian research in depression
Grover, S., Dutt, A., & Avasthi, A. (2010) · Indian Journal of Psychiatry · doi:10.4103/0019-5545.69231 · Cited by 177
Self-citationRavindran, A. V., Balneaves, L. G., Faulkner, G., Ortiz, A., McIntosh, D., Morehouse, R. L., Ravindran, L. N., Yatham, L. N., Kennedy, S. H., Lam, R. W. M., et al. (2018) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.16106 · Cited by 67
Research on antidepressants in India
Avasthi, A., Grover, S., & Aggarwal, M. (2010) · Indian Journal of Psychiatry · doi:10.4103/0019-5545.69263 · Cited by 18
Self-citationA systematic review and meta-analysis of trials of treatment of depression from India
Grover, S., & Sarkar, S. (2014) · Indian Journal of Psychiatry · doi:10.4103/0019-5545.124711 · Cited by 14
Self-citation
Flagged first, then by citations
5 of the 15 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- American Psychiatry Association. Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition, 2010; pp -152.
Cited by
Sorted by citations
Items 101–200 of 232
Mundula, T., Baldi, S., Gerace, E., & Amedei, A. (2023) · Biomedicines · doi:10.3390/biomedicines11020550 · Cited by 10
Richardson, L. G., & Brahmbhatt, A. (2020) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2020.09.002 · Cited by 10
Fibroblast Growth Factor: Promising Target for Schizophrenia
Talaeı, A., Farkhondeh, T., & Forouzanfar, F. (2020) · Current Drug Targets · doi:10.2174/1389450121666200628114843 · Cited by 6
Creative, Person-Centered Narrative Psychopharmacotherapy of Depression
Jakovljević, M. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-981-33-6044-0_23 · Cited by 3
Patel, M., Patel, V., Tiwari, D., Shah, V., Patel, D., & Chanpa, N. (2018) · doi:10.4172/2167-1044.1000324 · Cited by 5
“A number of clinical practice guidelines suggest SSRIs as first choice of treatment of MDD [4-6].”
BackgroundSalehinejad, M. A., Abdi, M., Dadashi, M., Habibi, M., Hallajian, A.-H., Sharifi, K., Khadem, A., Salvador, R., Ruffini, G., & Nitsche, M. A. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03560-0 · Cited by 4
“Antidepres-sants, especially Selective Serotonin Reuptake Inhibitors (SSRIs), and psychotherapeutic interventions, especially cognitive-behavioral therapy, are considered fi rst-line treatments for MDD with severe and mild to moderate severity [3, 4].”
Zhang, L.-S., Huang, K., Wu, F., Lam, C., & Huang, Z. (2025) · Mass Communication & Society · doi:10.1080/15205436.2025.2593468 · Cited by 4
Tsai, P.-Y., Chen, S.-M., Lin, C.-Y., Lee, M.-C., Huang, P.-H., Hsing, C., Peng, T.-R., & Lee, J.-A. (2025) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2025.10.001 · Cited by 4
Fixed dose combination dextromethorphan-bupropion: A hope for treatment resistant depression (TRD)
Das, R., Chakravarty, R., Gantait, V. V., & Bhattacharjee, S. (2025) · Indian Journal of Psychiatry · doi:10.4103/indianjpsychiatry_315_25 · Cited by 5
The impact of physical activity on depressive and anxiety disorders: A literature review
Woźniak, K., Woźniak, A., & Stasiak, M. (2024) · Quality in Sport · doi:10.12775/qs.2024.36.56456 · Cited by 6
“In particular situations, such as treatment-resistant depression, electroconvulsive therapy (ECT) or other modern methods like repetitive transcranial magnetic stimulation (rTMS) may be employed (Gautam et al., 2017).”
Liang, X., Guo, Y., Zhang, H., Wang, X., Li, D., Liu, Y., Zhang, J., Zhou, L., & Qiu, S. (2024) · International Journal of Clinical and Health Psychology · doi:10.1016/j.ijchp.2024.100526 · Cited by 4
“However, this study primarily aims to investigate the potential synergistic effects of non-pharmacological therapy, given that these two interventions are often combined in clinical practice (Gautam et al., 2017; Park et al., 2013).”
Venkata, P. K. T., Bolla, D., Donthu, R. K., Pathak, A., & Gudimetla, A. (2024) · Middle East Current Psychiatry · doi:10.1186/s43045-024-00420-x · Cited by 4
Tripathi, A., Agrawal, A., & Joshi, M. (2024) · Indian Journal of Psychiatry · doi:10.4103/indianjpsychiatry.indianjpsychiatry_784_23 · Cited by 4
“[41,42] Advantages • May reverse SD • Cost-saving approach.”
Ayyash, S., Davis, A. D., Alders, G. L., MacQUEEN, G. M., Strother, S. C., Hassel, S., Zamyadi, M., Arnott, S. R., Harris, J. K., Lam, R. W. M., et al. (2024) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2023.12.011 · Cited by 5
“Antidepressants are one of a number of treatment options used in the management of MDD (Gautam et al., 2017; Kennedy et al., 2016).”
BackgroundParmar, U. I., Puradkar, P., Kadam, K., Tadavi, F. M., Gajbhiye, S. V., Joshi, S. S., & Sohal, A. (2023) · Perspectives in Clinical Research · doi:10.4103/picr.picr_113_23 · Cited by 3
“[32] Only six FDCs containing antidepressants were prescribed.”
BackgroundSalian, H. H., Raghav, M., Rawat, V., & Divakar, A. (2023) · Indian Journal of Pharmacology · doi:10.4103/ijp.ijp_854_22 · Cited by 4
Khonglah, D., Pal, A., Mallik, N., Ray, D., Ghosal, M., & Acharya, R. (2023) · Indian Journal of Psychiatry · doi:10.4103/indianjpsychiatry.indianjpsychiatry_380_22 · Cited by 4
“[20] The statistical analysis was done using SPSS version 21.”
An Open-Label Rater-Blinded Randomized Trial of Vilazodone versus Escitalopram in Major Depression
Kumar, P. N. S., Suresh, R., & Menon, V. (2022) · Indian Journal of Psychological Medicine · doi:10.1177/02537176221127162 · Cited by 6
Smith, A. P., Lindeque, J. Z., & van der Walt, M. M. (2022) · Molecules · doi:10.3390/molecules27072094 · Cited by 4
Chung, P.-L., Huang, C.-W., Lee, M.-J., Yang, Y.-H., Chen, K.-J., Lu, M.-L., Weng, J.-C., & Chen, V. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s242798 · Cited by 4
Desai, R., & Sonawane, K. (2019) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2018.11.009 · Cited by 4
EEG-Based Classification in Psychiatry Using Motif Discovery
Kraljevska, M., Hlaváčková-Schindler, K., Miklautz, L., & Plant, C. (2025) · Neuroscience Informatics · doi:10.1016/j.neuri.2025.100242 · Cited by 3
Pantoji, M., Balachander, S., Prajapati, P., Arumugham, S. S., Venkatasubramanian, G., & Thirthalli, J. (2025) · Schizophrenia Research · doi:10.1016/j.schres.2025.08.018 · Cited by 3
Bhavya, Shetty, S., & Sadasivam, B. (2025) · Cureus · doi:10.7759/cureus.91829 · Cited by 2
“These guidelines emphasize systematic reassessment of diagnosis, optimization of antidepressant trials, and the considered use of augmentation, combination pharmacotherapy, or somatic interventions in a structured, stepwise manner [10].”
Aydemir, E., Yetkin, D., & Ayaz, F. (2025) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2025.578728 · Cited by 3
Factors associated with initial medication adherence with first-line therapy for depression.
Ganna, S., Li, J.-N., & Aparasu, R. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.120004 · Cited by 3
Adair, M., Bose, R., & Schmidt, S. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2382773 · Cited by 3
Fort-Rocamora, C., Casañas, R., Torres-Torres, A., Mas-Expósito, L., González, M., & Carbonero-Judez, M. T. (2023) · Enfermería clínica · doi:10.1016/j.enfcli.2023.11.004 · Cited by 3
A case of treatment-resistant depression in an older adult and a discussion of treatment options
Pope, E., Muthukrishnan, S., Phillips, J., & Phillips, S. M. (2021) · BJPsych Bulletin · doi:10.1192/bjb.2021.105 · Cited by 3
Tiwaria, V., Rastogi, S., Katiyarc, A., & Nischald, A. (2021) · Indian Journal of Traditional Knowledge · doi:10.56042/ijtk.v20i3.38869 · Cited by 3
Delibaş, D., & Erdoğan, E. (2021) · Perspectives in psychiatric care · doi:10.1111/ppc.12880 · Cited by 3
Erratum: Clinical practice guidelines for the management of depression
Gaur, N., Jagawat, T., Gautam, A., Raju, N., Tiwari, S., & Sidhana, R. (2017) · Indian Journal of Psychiatry · doi:10.4103/0019-5545.211279 · Cited by 3
“59 of Indian Journal of Psychiatry[1], the information in the section “Participants of expert group on CPG for Depression” is written incorrectly.”
Fort-Rocamora, C., Casañas, R., Torres-Torres, A., Mas-Expósito, L., González, M., & Carbonero-Judez, M. T. (2024) · Enfermería Clínica (English Edition) · doi:10.1016/j.enfcle.2023.11.004 · Cited by 2
Tabarraei, M., Jabbari, S., Abdi, M., Dadashi, M., & Salehinejad, M. A. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.121595 · Cited by 2
Clinical practice guideline for assessment and management of depression in India
Tripathi, A., Shukla, R., Kar, S. K., Gupta, S., Saran, P., Pattojoshi, A., & Rao, T. (2026) · Indian Journal of Psychiatry · doi:10.4103/indianjpsychiatry_1321_25 · Cited by 4
Schmid, M. T., Ronold, E. H., Løchen, M., & Hammar, Å. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1623126 · Cited by 2
“Over 50% of patients experience new episodes within two years of onset (10), and between 50% and 85% of patients will experience multiple episodes throughout their life course (11).”
Rehabilitation for Persons with Mental Illness: What a Clinician Needs to Know?
Sivakumar, T., Angothu, H., & Nishanth, K. N. (2025) · Indian Journal of Social Psychiatry · doi:10.4103/ijsp.ijsp_296_25 · Cited by 2
Cheng, V., Sayre, E. C., Cheng, V., Loree, J., Gill, S., Murphy, R., Howren, A., & de Vera, M. (2025) · BMJ Oncology · doi:10.1136/bmjonc-2024-000690 · Cited by 2
Magarbeh, L., Elsheikh, S. S. M., Islam, F., Marshe, V. S., Men, X., Tavakoli, E., Kronenbuerger, M., Kloiber, S. M., Frey, B. N., Milev, R. V., et al. (2025) · The Canadian Journal of Psychiatry · doi:10.1177/07067437251329073 · Cited by 2
Changes in patient-reported outcomes during admission to a South African psychiatric facility
Motshudi, L., Hann, C.-D., Kloppers, M., Luhandjula, T., Phalatse, T., Pretorius, D., Smith, D., Smith, M., van der Westhuizen, M., & Rodseth, R. N. (2024) · South African Journal of Psychiatry · doi:10.4102/sajpsychiatry.v30i0.2258 · Cited by 2
Electroconvulsive Therapy Beyond Schizophrenia and Bipolar Disorders
Sahoo, S., & Naik, S. S. (2024) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-024-00273-y · Cited by 2
“Almost all the treatment guidelines promote and advocate the use of ECT in treat-ment-resistant depression [6–8].”
Kuc, A., Stachura, A., Jażdżyk, P., Grzelińska, J., & Święcicki, Ł. (2024) · Postepy psychiatrii neurologii · doi:10.5114/ppn.2024.135531 · Cited by 2
“First line treatment for PTSD is trauma focused psychotherapy, including eye movement desensitization and reprocessing therapy (EMDR) [5-8] whereas electroconvulsive therapy (ECT) is one of the most effective treatments for MDD [9, 10].”
BackgroundJaved, N., Binny, B., Sequeira, D. V., Mathew, V. K., & Pandiyan, K. (2023) · Journal of Psychiatry Spectrum · doi:10.4103/jopsys.jopsys_41_23 · Cited by 2
Chail, A., Bhat, P., Singh, H., & Saini, R. K. (2022) · Industrial Psychiatry Journal · doi:10.4103/ipj.ipj_16_22 · Cited by 2
“Pharmacological augmentation treatment [13] was in the form of lithium, serotonin-dopamine antagonist (SDA, buspirone or thyroxine).”
Mandal, S., Acharya, R., Mallik, N., Jain, S. M., Ghosh, A., Ghosal, M., & Pal, A. (2022) · Indian Journal of Psychological Medicine · doi:10.1177/02537176221101487 · Cited by 2
Goldman, P., Pedersen, E., Bailey, M. J., Hasse, M., & Koo, M. (2022) · Brain stimulation · doi:10.1016/j.brs.2022.04.013 · Cited by 4
“Continued research in the form of double blind, randomized control trials that examine rTMS depression outcomes over an age continuum should be conducted to further assesses the effect of age on rTMS efficacy for MDD. Declaration of competing interest The authors declare that they have no known competing financial int…”
BackgroundInfluentialGoud, U. K., Hasanthi, K., Pandiri, K., & Manipriya, K. (2021) · JOURNAL OF DRUG VIGILANCE AND ALTERNATIVE THERAPIES · doi:10.52816/jdvat.2021.1201 · Cited by 2
Young, A., Baune, B., Benatti, B., Bennabi, D., Estercam, S., Gorwood, P., Gutiérrez-Rojas, L., Martiadis, V., Molero, P., Normann, C., et al. (2026) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2026.112907 · Cited by 1
Francis, A. J. A., Bajpai, A., Balasubramani, N. P., Tiwari, H. P., Singh, S., Chawla, K., Singh, A., Chaudhari, D., & Balasubramani, P. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1823806 · Cited by 1
“Medication was chosen according to the judgment of the attending physician and in accordance with the Clinical Practice Guidelines (CPG; 31).”
Zhao, B., Huang, X., Xing, Y., Luo, H., Ye, Z., Xu, W., & Shao, J. (2026) · Sleep Health · doi:10.1016/j.sleh.2026.04.007 · Cited by 1
Grover, S., Naskar, C., & Chakrabarti, S. (2026) · Annals of Indian Psychiatry · doi:10.4103/aip.aip_28_23 · Cited by 1
Self-citationSegal, S. K., Weber, C. L., Gruschkus, S. K., Kaplan, A. M., Miller, S., & Ivany, C. (2026) · Psychiatric Services · doi:10.1176/appi.ps.20250258 · Cited by 1
Shin, D., Ham, B., & Kim, K. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.121307 · Cited by 1
Islam, F., Muthukanagaraj, P., Chen, M.-H., Zhan, L., Leow, A. D., & Shi, C. (2025) · JMIR XR and spatial computing · doi:10.2196/82422 · Cited by 1
Tamm, J., Takano, K., Just, L., Ehring, T. W., Rosenkranz, T., & Kopf‐Beck, J. (2025) · Behavior Therapy · doi:10.1016/j.beth.2025.08.002 · Cited by 1
Han, J., Kim, M., Kim, Y., Lee, S. H., Shin, S., & Choi, Y. J. (2025) · Medicina · doi:10.3390/medicina61061103 · Cited by 3
“…properties, may further increase the risk of falls, cognitive impairment, and cardiovascular events in elderly persons with neurodegenerative disorders, and the guidelines strongly recommend prescribing antidepressants with the lowest potential for anticholinergic effects in dementia patients [28].”
InfluentialPerinatal depression and suicidal behaviour: the need for timely intervention
Rathore, G., Sharma, K., Yadav, N., & Jha, S. (2025) · International Journal of Reproduction Contraception Obstetrics and Gynecology · doi:10.18203/2320-1770.ijrcog20250896 · Cited by 2
A Brief Review of the Postpartum Depression Medication Zuranolone
Perez, A. G., Saaraswat, M., & Oldak, S. E. (2025) · American Journal of Psychiatry Residents Journal · doi:10.1176/appi.ajp-rj.2025.200304 · Cited by 1
Clinical practice guidelines for assessment and management of cognitive impairment in schizophrenia
Grover, S., Mohapatra, D., Vaitheswaran, S., Mehta, U. M., Venkatasubramanian, G., & Thirthalli, J. (2025) · Indian Journal of Psychiatry · doi:10.4103/indianjpsychiatry.indianjpsychiatry_690_24 · Cited by 3
Self-citationObjective outcome prediction in depression through functional MRI brain network dynamics.
Pilmeyer, J., Rademakers, S., Lamerichs, R., van Kranen-Mastenbroek, V. V., Jansen, J., Breeuwer, M., & Zinger, S. (2024) · Psychiatry research. Neuroimaging · doi:10.1016/j.pscychresns.2024.111945 · Cited by 1
Sleep Hygiene Education as a Treatment for Depression in Adolescents
Thibault, D., Derouin, A. L., Cain, L. A., Thibault, N. E., & Roberts, J. (2024) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2024.105114 · Cited by 1
The relationship between self-reported antipsychotics side effects and depression in Saudi Arabia
AlRuthia, Y. S. (2024) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2024.102164 · Cited by 1
“However, pharmacotherapies, such as antidepressants and antipsychotics, are the mainstay in mental disorders treatment (Locke et al., 2015, Gautam et al., 2017, Keepers et al., 2020, Kate and Zachary 2022).”
BackgroundSuganya, M., & Kalabarathi, S. (2024) · International journal of Nutrition Pharmacology Neurological Diseases · doi:10.4103/ijnpnd.ijnpnd_42_24 · Cited by 1
Dang, Y., Lu, B., Vanderwal, T., Castellanos, F. X., & Yan, C. (2024) · Psychological Medicine · doi:10.1017/s0033291724001156 · Cited by 3
“As suggested by current treatment guidelines, at least 4 weeks at a therapeutic dose are required to assess if a particular antidepressant is working (Gautam, Jain, Gautam, Vahia, & Grover, 2017).”
Bhachech, H., Nath, K., Sidana, R., Shah, N., Nagpal, R., Sathianathan, R., Kakkad, A., & Korukonda, K. (2024) · Cureus · doi:10.7759/cureus.52878 · Cited by 1
Care Throughout the Journey-The Interaction Between Primary Care and Palliative Care.
Taylor, E. P., Vellozzi-Averhoff, C., & Vettese, T. (2023) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2023.04.002 · Cited by 1
Alfaifi, A., & Althemery, A. (2022) · Scientific Reports · doi:10.1038/s41598-022-22164-6 · Cited by 1
Ramezani, A., Kheirkhah, F., Zabihi, E., Shirafkan, H., & Moudi, S. (2022) · Global Journal of Medical, Pharmaceutical, and Biomedical Update · doi:10.25259/gjmpbu_16_2022 · Cited by 1
Impact of COVID-19 pandemic on outpatient depression treatment and NHIF expenditure
Mitkova, Z., Dimitrova, M., Mitkov, J., & Petrova, G. (2022) · Journal of Applied Pharmaceutical Sciences · doi:10.7324/japs.2022.120511 · Cited by 1
“Hence, it is not a result of pandemic expansion and the final results are based on clinical practice recommendations and treatment approaches applied before 2020 (Gautam et al., 2017).”
BackgroundHyperbolic dose reduction of escitalopram mitigates withdrawal syndrome: A case report
Gallo, A. T., & Hulse, G. K. (2022) · Psychiatry Research Case Reports · doi:10.1016/j.psycr.2022.100009 · Cited by 1
Taylor, M., Kaplan, T., Mulvey, P., & Miller, M. K. (2019) · International Journal of Law and Psychiatry · doi:10.1016/j.ijlp.2019.101474 · Cited by 1
Cadwallader, J. (2018) · theses.fr (ABES) · doi:10.70675/ba108b5az48b1z4f64zae0dz493bafa9ff1c
Age differences in the effects of task difficulty and outcome on affective forecasting bias
Liu, Y., Hong, Y., Wang, N., Zhang, X.-J., & Xu, G. (2025) · Personality and Individual Differences · doi:10.1016/j.paid.2025.113331 · Cited by 1
Thakur, J., S, K., Paika, R., Dhirar, N., Nangia, R., Kunjan, K., Duseja, A., Gupta, A., Chockalingam, A., Aggarwal, A., et al. (2020) · International Journal of Noncommunicable Diseases · doi:10.4103/2468-8827.291731 · Cited by 1
Self-citationAn exploratory study evaluating the concept of difficult-to-treat schizophrenia
Grover, S., Naskar, C., & Chakrabarti, S. (2026) · Geopsychiatry · doi:10.1016/j.geopsy.2026.100135
Self-citationEFFICACY AND SAFETY OF PSILOCYBIN IN TREATMENT-RESISTANT DEPRESSION: A REVIEW
Gawin, M., Koziara, E., Gadzina, M., Gawlak, J., Kuświk, M. K., Tarnawska, Z., Figiel, K., Sontag, W., Zawisza, M., & Golec, A. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.6573
Abu-Zaid, A., Alyoubi, R., Alyahyawi, H., Saleh, S. A., Adly, H., Alabduljabbar, K., Baradwan, S., Bayazeed, B. M., & Ahmad, S. O. (2026) · Scottish Medical Journal · doi:10.1177/00369330261487638
Afrin, S., Moni, S., Alim, S. M. A. H. M., Khatun, S., Rahman, F., & Mottalab, M. A. (2026) · TAJ Journal of Teachers Association · doi:10.70818/taj.v39i03.0713
Socransky, O., Friedman, Z., Gutterman, D. D., Shinfeld, A., Koren, D., Rimon, J., Kumbhare, D. A., Clarke, H. A., Slepian, P. M., Lidor, R., et al. (2026) · Cardiology in Review · doi:10.1097/crd.0000000000001447
Singh, S., Shenoy, S., & Praharaj, S. K. (2026) · Indian Journal of Psychiatry · doi:10.4103/indianjpsychiatry_8_26
“Regarding clinical characteristics, the APP group had a significantly longer duration of illness ( P = 0.004; d = 0.55), a higher total CPZ equivalent dose ( P < 0.001; d = 1.21), and more frequent THP use ( P = 0.01; φ = 0.23) than the APM group [Tables 1, 2 and Figures 1, 2].”
InfluentialGeoghegan, E. M., Hagenauer, M. H., Hernandez, E., Espinoza, S., Flandreau, E. I., Nguyen, P. T., Santiago, A. N., Bhuiyan, M. R., Mensch, S., Watson, S. J., et al. (2026) · Journal of Neurochemistry · doi:10.1111/jnc.70502 · Cited by 1
“These include selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs) (Gautam et al. 2017; Harmer et al. 2017; Artigas et al. 2002).”
Religious Psychopathology: Overview of Clinical, Cultural, and Neurobiological Perspectives
Synadinakis, E., Delis, A., Doska, A., Mourtakos, S., Tzavellas, E., & Doskas, T. K. (2026) · Religions · doi:10.3390/rel17060719
Presseller, E. K., Farooq, F., Reyes-Madriz, E., Rouleau-Tang, M., Jacobson, N. C., Thomas, J. G., & Marsch, L. A. (2026) · JMIR Research Protocols · doi:10.2196/104849
Sepas, A., Alkafaji, H., Atici, V., Bjarkam, C. R., & Moos, T. (2026) · Deep Brain Stimulation · doi:10.1016/j.jdbs.2026.06.004
Shrivastava, A., Vaibhav, K., Gupta, M., Verma, P., Priya, A., Pandey, A., Gupta, S., Agarwal, K., Kumar, G., Shah, N., et al. (2026) · Annals of Indian Psychiatry · doi:10.4103/aip.aip_74_26
Hierarchical Graph Convolutional Network with Depression-Oriented Priors
Li, Q., Ren, M., Liu, X., Yao, L., & Huang, Y. (2026) · IEEE International Conference on Acoustics Speech and Signal Processing · doi:10.1109/icassp55912.2026.11461409
Hetrick, S. E., Berk, M., Dean, O. M., Chanen, A., McGorry, P., Cotton, S. M., Torok, M., Catania, L. S., Davey, C. G., & Witt, K. G. (2026) · European Child and Adolescent Psychiatry · doi:10.1007/s00787-026-03032-4
Baune, B., Prabhakaran, A., Patel, M., Grübel, S. E. F., Varma, J., Patel, M., & Gupta, S. N. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1719639
Hafeez, Z., Bilal, M., Batool, F., Mahnoor, A., Tehreem, S., & Abbas, S. (2026) · ACADEMIA International Journal for Social Sciences · doi:10.63056/academia.5.3(s8).2026.2103
“…evidence notwithstanding, ACE studies are still skewed towards the Western settings, with major gaps in culturally sensitive, gender-sensitive studies on coping and mental health among populations of South Asian universities (Gautam, Jain, Gautam, Vahia, and Grover, 2017; Patel et al., 2018).”
Coprescription of antipsychotics and benzodiazepines at hospital discharge.
Demourgues, M., Richaud, A., Thiec, J., Debruyne, A., Guillemin, S., Tournier, M., Salvo, F., & Queuille, E. (2026) · L'Encephale · doi:10.1016/j.encep.2025.10.010
Zanao, T. A., Salvan, P., Razza, L. B., da Silva, P. H. R., Brunoni, A. R., & O’Shea, J. (2026) · Scientific Reports · doi:10.1038/s41598-026-40364-2
Cotardo, F., Koumantakis, E., Rossini, P. G., Malandrone, F., Berchialla, P., Ostacoli, L., & Carletto, S. (2026) · Frontiers in Psychology · doi:10.3389/fpsyg.2025.1688526
Fetahović, E., Selaković, D., Mitrović, M. M., Jovicic, N. U., Marković, B. S., Milosavljević, J., Radmanović, B., Milovanovic, D., Ljujić, B., Rosic, G. L., et al. (2026) · Genes · doi:10.3390/genes17010057
“Therapeutic options for the treatment of MDD can be broadly divided into pharmacological and non-pharmacological [8].”
Correll, C. U., Purushottamahanti, P., Subramaniam, K., Bayan, B., Cook, J., Palmer, E. O. C., Yeow, J., & Lipunova, N. (2026) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s563433
Aminesmaeili, M., Baheshmat, S., Rahimi-Movaghar, A., Ardestani, S. M. S., Samadi, R., Hajebi, A., Farzy, Y., Moghimi-Sarani, E., Khatibzadeh, S., & Shahraz, S. (2026) · Archives of Iranian medicine · doi:10.34172/aim.34141
Zhang, X.-D. (2025) · Educational Gerontology · doi:10.1080/03601277.2025.2595151
Rai, U., Paliwal, S., Prasad, S., Kumar, G., Dey, P., & Mehta, V. S. (2025) · Journal of ECT · doi:10.1097/yct.0000000000001210
García, N. B., Torres, J. M., Galvis-Pérez, Y., Martínez, S. M., & Gómez, G. F. V. (2025) · Gerencia y Políticas de Salud · doi:10.11144/javeriana.rgps24.dacp · Cited by 1
Telepsychiatry in addiction treatment: Evaluating India’s telemedicine guidelines
Muhammed, J. K., Negi, D., & Roshan, B. (2025) · Indian Journal of Psychiatry · doi:10.4103/indianjpsychiatry_634_25 · Cited by 1
“[38] This will force the clinician to call the patient for an in person visit if they want to prescribe other medications that are equally effective or more suitable for the patient, which beats the purpose of telemedicine.”
Faradiba, A. T., & Kurniawan, F. (2025) · Gadjah Mada Journal of Professional Psychology (GamaJPP) · doi:10.22146/gamajpp.99687
“Treatment typically begins with a low dose and is adjusted according to the patient’s response and the appearance of side effects (Grover et al., 2017).”
Metadata
- Authors
- Grover, S., Gautam, S., Jain, A., Gautam, M., & Vahia, V.
- Affiliations
- Post Graduate Institute of Medical Education and Research (IN)
- Employees' State Insurance Model Hospital (IN)
- Corresponding author
- Grover, Sandeep
- ORCID
- Grover, Sandeep
- Venue
- Indian Journal of Psychiatry
- Published
- 2017
- Volume
- 59
- Issue
- 5
- Pages
- 34
- ISSN
- 0019-5545 (ISSN-L)
- PMC
- PMC5310101
- OpenAlex
- W2568301711
- Cited by
- 269
- References
- 15
- Citations by year
- 2026: 28 · 2025: 44 · 2024: 52 · 2023: 29 · 2022: 29 · 2021: 29 · 2020: 29 · 2019: 12 · 2018: 10 · 2017: 3
- FWCI
- 10.31
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by-nc-sa
- Locations
- Indian Journal of Psychiatry (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- depression, depression treatment, depression assessment, diagnostic criteria, somatic symptoms of depression, antidepressant treatment, antidepressant side effects, antidepressant discontinuation, antidepressant switching, antidepressant augmentation, antidepressant combination therapy, depression recurrence, relapse prevention, psychotherapy, suicide risk, comorbid depression, quality of life, role functioning, global burden of disease, health care costs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review